NASDAQ:KRYS • US5011471027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KRYSTAL BIOTECH INC (KRYS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Wolfe Research | Initiate | Peer Perform |
| 2026-02-25 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-18 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-17 | Jefferies | Maintains | Buy -> Buy |
| 2026-02-02 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-22 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-12 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-09 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-06 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-11-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-07-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-10 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-07-01 | Clear Street | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50.699M | 290.515M 473.02% | 389.13M 33.94% | 544.31M 39.88% | 731.42M 34.38% | 972.43M 32.95% | 1.233B 26.80% | 1.495B 21.25% | 1.718B 14.92% | 1.422B -17.23% | 1.83B 28.69% | |
| EBITDA YoY % growth | -92.22M 20.60% | 109.162M 218.37% | 167.019M 53.00% | 238.36M 42.71% | 326.98M 37.18% | 641.27M 96.12% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -97.227M 19.11% | 103.195M 206.14% | 161.295M 56.30% | 256.2M 58.84% | 375.66M 46.63% | 596.27M 58.73% | 830.46M 39.28% | 1.059B 27.52% | 1.255B 18.51% | 1.053B -16.10% | 1.329B 26.21% | |
| Operating Margin | -191.77% | 35.52% | 41.45% | 47.07% | 51.36% | 61.32% | 67.35% | 70.84% | 73.05% | 74.05% | 72.62% | |
| EPS YoY % growth | -3.40 24.61% | 2.99 187.94% | 6.85 129.10% | 7.87 14.92% | 11.13 41.39% | 15.14 36.02% | 25.87 70.91% | 32.13 24.18% | 36.72 14.30% | 20.06 -45.37% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.44 20.15% | 1.74 34.81% | 2.04 -23.16% | 2.30 35.45% | 2.62 81.81% | 3.06 75.95% | 3.48 70.18% | 4.23 83.83% |
| Revenue Q2Q % growth | 114.41M 29.74% | 130.17M 35.53% | 144.96M 48.22% | 156.42M 46.04% | 167.54M 46.44% | 189.18M 45.33% | 208.55M 43.87% | 241.58M 54.44% |
| EBITDA Q2Q % growth | 49.35M 31.30% | 56.901M 35.27% | 62.322M 36.86% | 70.895M 41.81% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 38.469M 6.34% | 47.614M 21.13% | 58.711M 41.90% | 64.831M 46.44% | N/A | N/A | N/A | N/A |
All data in USD
18 analysts have analysed KRYS and the average price target is 319.36 USD. This implies a price increase of 22.79% is expected in the next year compared to the current price of 260.08.
KRYSTAL BIOTECH INC (KRYS) will report earnings on 2026-05-04, before the market open.
The consensus EPS estimate for the next earnings of KRYSTAL BIOTECH INC (KRYS) is 1.44 USD and the consensus revenue estimate is 114.41M USD.
The consensus rating for KRYSTAL BIOTECH INC (KRYS) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.